Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 16/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.39 |
| ▸ | TNNI3K | Q59H18 | 10/20 | 0.39 |
| ▸ | BRAF | P15056 | 10/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | KMO | O15229 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19365657 | 0.90 | NPC1 (0.38) | PIK3CDPIK3CAPIK3CGKDM1AKMO | |
| SCHEMBL19670449 | 0.89 | KDR (0.40) | KDRMAPK14TNNI3KBRAFPIK3CD | |
| SCHEMBL19365601 | 0.89 | CNR1 (0.36) | — | |
| SCHEMBL19365769 | 0.86 | MPL (0.43) | KDRMAPK14TNNI3KBRAFPIK3CD | |
| SCHEMBL19670563 | 0.83 | ALOX15 (0.44) | KDRPIK3CDPIK3CAPIK3CGKDM1A | |
| SCHEMBL19365643 | 0.82 | KMO (0.36) | PIK3CDPIK3CAPIK3CGKDM1AKMO | |
| SCHEMBL19365509 | 0.81 | PHGDH (0.38) | PIK3CDPIK3CAPIK3CGEGFRKDM1A | |
| SCHEMBL19365791 | 0.80 | FGFR4 (0.34) | KDRMAPK14TNNI3KBRAF | |
| SCHEMBL19365862 | 0.79 | KDM1A (0.40) | PIK3CDPIK3CAPIK3CGKDM1AKMO | |
| SCHEMBL19365786 | 0.79 | RHOA (0.37) | MAPK14BRAFPIK3CDPIK3CAPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
| US-9765075-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | KDR 1697/4885MAPK14 2116/4885TNNI3K 1750/4885 |
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | SIRT1, SIRT3, SIRT2 | KDR 1697/4885MAPK14 2116/4885TNNI3K 1750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.